First, MOG may serve as an autoantigen that, in conjunction with AQP4, acts synergistically to produce the immune-mediated tissue injury typically present in NMO and MS patients with both sets of these autoantigens. The gene discussed is AQP4; the disease is myeloid sarcoma.